Immunovant, Inc. Quarterly Income Tax Expense (Benefit) in USD from Q4 2018 to Q2 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Immunovant, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q4 2018 to Q2 2024.
- Immunovant, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $77K.
- Immunovant, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $655K.
- Immunovant, Inc. annual Income Tax Expense (Benefit) for 2023 was $567K, a 6200% increase from 2022.
- Immunovant, Inc. annual Income Tax Expense (Benefit) for 2022 was $9K.
- Immunovant, Inc. annual Income Tax Expense (Benefit) for 2021 was -$84K, a 76.5% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)